The Widening Gap in Cancer Surgery Wait Times
Patients diagnosed with non-metastatic breast, colon, lung, pancreatic, gastric, and esophageal cancers in the United States face increasingly prolonged wait times for necessary surgical interventions compared to a decade ago, according to a large-scale study published in JAMA Surgery. Timeliness stands as a core metric of healthcare quality. Medical literature consistently links treatment delays to diminished survival rates, elevated patient anxiety, and heightened psychological distress.
The investigation evaluates health records from over 2.7 million patients diagnosed with stage I through III non-metastatic tumors requiring surgical resection between 2012 and 2023.
Led by Timothy Donahue at the University of California, Los Angeles, the research team segmented the multi-year timeline into distinct intervals to track longitudinal shifts in surgical scheduling efficiency.
Tracking Shifts Across Four Distinct Cohorts
To measure changes in access speed accurately, the study divided the twelve-year span into four distinct cohorts: 2012–2015, 2016–2019, 2020–2021, and 2022–2023. By comparing these periods, investigators identified a consistent upward trajectory in the number of days elapsing between an initial confirmed diagnosis and the execution of the primary tumor resection.
While oncological advancements have steadily improved overall survival probabilities and treatment efficacy, operational delays have introduced a counterbalancing risk.
Thoracic and Gastrointestinal Malignancy Pathways
The analysis specifically tracked six distinct cancer categories: breast, colon, lung, pancreatic, gastric, and esophageal cancers.